Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guangxi Wuzhou Zhongheng Group Co.,Ltd (600252.SS)
Wuzhou, CN
Guangxi Wuzhou Zhongheng Group Co., Ltd., operating from Wuzhou, China, specializes in the research, development, manufacturing, and distribution of pharmaceutical products across the nation. The company's diverse range of medicinal preparations includes pills, capsules, injections, and tablets, formulated to address various health concerns such as cardiovascular and cerebrovascular disorders, physical injuries, gynecological conditions, and respiratory ailments. In addition to its core pharmaceutical business, Guangxi Wuzhou Zhongheng Group also produces health food items, notably under its DOUBLE MONEY brand. Furthermore, its offerings encompass health-oriented functional beverages, various forms of turtle paste (including smokable and jelly types), and other related wellness products.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.37% | +0.45% | -9.76% | -15.27% | -23.45% | -18.98% | -14.94% | -11.90% | -23.97% | -47.89% | -3.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-23.0% Q1'26: -52.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+2.1% Q1'26: -290.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-32.8% Q1'26: -1.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-26.5% Q1'26: -5.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-9.6% Q1'26: -1.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-7.4% ★ Q1'26: -4.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-5.07× Q1'26: -27.30× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.00% | 15.6K | 0.40% |
| 2 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 67.3K | 0.17% |
| 3 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 67.3K | 0.17% |
| 4 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 12.4K | 0.24% |
| 5 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 12.4K | 0.24% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.7K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 19.5K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 963.2K | 0.06% |
| 9 | Vanguard Total World Stock ETF VT | 0.00% | 288.2K | 0.06% |
| 10 | Vanguard FTSE All-World UCITS ETF (USD) Accumulating VWRA.L | 0.00% | 196.2K | 0.19% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hai Run Wang | Deputy GM, General Counsel, Secretary, Chief Compliance Officer & Director | — | male |
| Hui Ge | Financial Officer | — | male |
| Lin Xiao | Deputy General Manager | — | male |
| Ming Chen | Deputy General Manager | — | male |
| Peng Li | Accounting Supervisor | — | — |
| Tian Jiao Wang | Deputy General Manager | — | male |
| Weimin Peng | Deputy General Manager | — | male |
| Xiangyong Wang | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600252.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
